Nifty
:
20267.90
Sensex
:
67481.19
134.75 (0.67%)
492.75 (0.74%)
Nifty
Sensex
:
:
20267.90
67481.19
134.75 (0.67%)
492.75 (0.74%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
70/99

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
1033.75
01-Dec-2023
  • Open
  • High
  • Low
  • Previous Close
  •  1049.00
  •  1059.65
  •  1031.00
  •  1041.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1227116
  •  12786.90
  •  1059.65
  •  397.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 60,562.61
  • 26.04
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 59,736.38
  • 0.29%
  • 2.15

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 0.59%
  • 6.16%
  • FII
  • DII
  • Others
  • 22.45%
  • 17.94%
  • 1.03%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.87
  • 4.90
  • 0.11

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.71
  • -1.21
  • -6.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.09
  • -3.98
  • -29.02

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.78
  • 13.61
  • 12.61

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.04
  • 2.09
  • 1.78

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.37
  • 8.98
  • 8.45

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Net Sales
7,219.42
5,739.37
25.79%
6,850.52
6,235.92
9.86%
6,472.96
5,809.37
11.42%
6,407.13
6,002.22
6.75%
Expenses
5,845.98
4,948.58
18.13%
5,699.15
5,299.44
7.54%
5,470.78
4,834.97
13.15%
5,452.72
4,985.95
9.36%
EBITDA
1,373.44
790.79
73.68%
1,151.37
936.48
22.95%
1,002.18
974.40
2.85%
954.41
1,016.27
-6.09%
EBIDTM
19.02%
13.78%
16.81%
15.02%
15.48%
16.77%
14.90%
16.93%
Other Income
186.98
57.19
226.95%
116.33
40.62
186.39%
134.91
48.88
176.00%
92.65
64.99
42.56%
Interest
68.18
25.29
169.59%
56.55
14.63
286.53%
55.60
9.21
503.69%
44.96
16.13
178.74%
Depreciation
417.50
298.10
40.05%
326.56
279.51
16.83%
345.57
253.57
36.28%
321.40
299.05
7.47%
PBT
1,074.74
524.59
104.87%
814.84
682.96
19.31%
735.92
597.74
23.12%
680.70
800.87
-15.00%
Tax
323.70
112.99
186.49%
242.32
158.61
52.78%
224.15
17.49
1,181.59%
189.10
189.49
-0.21%
PAT
751.04
411.60
82.47%
572.52
524.35
9.19%
511.77
580.25
-11.80%
491.60
611.38
-19.59%
PATM
10.40%
7.17%
8.36%
8.41%
7.91%
9.99%
7.67%
10.19%
EPS
12.92
6.99
84.84%
9.74
8.88
9.68%
8.64
9.84
-12.20%
8.38
10.32
-18.80%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
26,950.03
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
Net Sales Growth
13.30%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
 
Cost Of Goods Sold
12,229.98
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
Gross Profit
14,720.05
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
GP Margin
54.62%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
Total Expenditure
22,468.63
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
Power & Fuel Cost
-
842.63
626.86
589.28
587.68
556.79
470.95
437.14
419.26
359.60
349.84
% Of Sales
-
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
Employee Cost
-
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
% Of Sales
-
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
Manufacturing Exp.
-
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
% Of Sales
-
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
General & Admin Exp.
-
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
% Of Sales
-
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
Selling & Distn. Exp.
-
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
359.60
% Of Sales
-
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
4.44%
Miscellaneous Exp.
-
698.93
419.58
576.06
529.75
413.24
298.75
203.97
212.65
227.09
359.60
% Of Sales
-
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
1.52%
EBITDA
4,481.40
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
EBITDA Margin
16.63%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
Other Income
530.87
290.59
322.58
380.85
191.87
155.32
101.98
115.89
203.80
96.71
21.56
Interest
225.29
140.48
48.64
74.49
305.13
262.60
77.72
66.72
256.70
159.87
310.16
Depreciation
1,411.03
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
312.53
PBT
3,306.20
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
Tax
979.27
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
363.45
Tax Rate
29.62%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
PAT
2,326.93
1,927.50
2,648.15
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
PAT before Minority Interest
2,333.82
1,927.65
2,647.11
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
Minority Interest
6.89
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
1.50
4.51
3.78
PAT Margin
8.63%
7.75%
11.29%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
PAT Growth
9.37%
-27.21%
-50.87%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
34.35%
 
EPS
39.72
32.90
45.20
92.00
48.82
40.31
41.30
39.20
34.54
26.89
20.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
Share Capital
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.52
29.20
29.15
Total Reserves
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
Non-Current Liabilities
866.87
903.10
807.27
555.09
358.13
594.11
102.07
583.85
1,591.60
1,493.91
Secured Loans
618.96
249.21
168.49
0.00
48.88
451.20
177.59
380.10
773.54
1,101.31
Unsecured Loans
0.00
0.00
0.00
0.00
131.07
0.00
3.81
362.71
587.93
178.05
Long Term Provisions
172.72
171.79
157.11
74.71
46.54
55.86
39.13
23.36
24.35
9.18
Current Liabilities
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
Trade Payables
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
Other Current Liabilities
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
387.68
Short Term Borrowings
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
Short Term Provisions
412.13
228.59
382.28
511.72
384.67
294.23
261.36
132.93
218.24
126.60
Total Liabilities
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
Net Block
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
Gross Block
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
Accumulated Depreciation
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
Non Current Assets
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
Capital Work in Progress
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
Non Current Investment
391.74
618.30
431.22
554.69
360.20
311.52
245.85
122.94
0.14
19.76
Long Term Loans & Adv.
794.00
575.33
658.44
378.34
396.64
261.91
256.48
236.56
455.27
789.04
Other Non Current Assets
67.39
37.52
53.03
36.61
38.62
86.93
81.29
32.24
30.25
18.40
Current Assets
21,459.91
18,043.59
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
Current Investments
151.00
378.85
159.79
0.02
0.02
0.02
0.02
0.02
19.65
0.03
Inventories
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
Sundry Debtors
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
Cash & Bank
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
Other Current Assets
2,247.10
393.95
601.29
489.35
2,715.72
1,977.28
1,596.81
831.25
659.57
448.46
Short Term Loans & Adv.
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
237.22
Net Current Assets
9,966.13
9,887.61
9,158.46
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
Total Assets
39,126.74
33,554.03
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
646.28
PBT
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
Adjustment
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
515.12
Changes in Working Capital
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
Cash after chg. in Working capital
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
990.23
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
Net Fixed Assets
-503.76
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
Net Investments
-1,637.42
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
Others
-1,836.57
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
-513.08
Cash from Financing Activity
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
Net Cash Inflow / Outflow
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
-54.82
Opening Cash & Equivalents
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
Closing Cash & Equivalent
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
458.10
419.46
374.29
287.16
237.08
199.36
159.96
124.50
88.29
64.33
ROA
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
ROE
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
ROCE
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
Fixed Asset Turnover
2.95
3.24
3.73
4.12
4.36
2.44
2.96
2.79
2.55
2.08
Receivable days
30.42
28.69
29.37
29.85
29.56
64.66
89.16
106.53
91.84
93.55
Inventory Days
57.65
63.29
62.82
57.72
59.64
112.70
101.43
100.27
88.91
94.82
Payable days
117.74
108.60
111.03
53.30
58.56
67.77
75.73
81.70
67.49
71.06
Cash Conversion Cycle
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
113.25
117.31
Total Debt/Equity
0.18
0.10
0.23
0.33
0.50
0.41
0.36
0.69
0.86
1.01
Interest Cover
19.60
70.34
100.33
13.32
12.76
42.66
46.80
11.69
14.56
5.94

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Aurobindo Pharma’s arm gets USFDA’s final nod for Budesonide Inhalation Suspension
    30th Nov 2023, 12:14 PM

    The product is expected to be launched in FY25

    Read More
  • Aurobindo Pharma gets USFDA’s final nod for Darunavir Tablets
    29th Nov 2023, 12:14 PM

    The product will be launched on November 29, 2023

    Read More
  • Aurobindo Pharma incorporates wholly owned subsidiary
    22nd Nov 2023, 14:10 PM

    Auro Trading is incorporated for carrying on trading in generic formulations business

    Read More
  • USFDA conducts inspection at units of Aurobindo Pharma’s arm
    17th Nov 2023, 16:37 PM

    The inspection closed with zero observations

    Read More
  • Aurobindo Pharma reports 83% rise in Q2 consolidated net profit
    10th Nov 2023, 14:30 PM

    Total consolidated income of the company increased by 27.77% at Rs 7,406.40 crore for Q2FY24

    Read More
  • Aurobindo Pharma gets nod to acquire stake in Theranym Biologics
    10th Nov 2023, 10:57 AM

    The Board of Directors of the Company at its meeting held November 9, 2023, has approved the same

    Read More
  • Aurobindo Pharma - Quarterly Results
    9th Nov 2023, 19:52 PM

    Read More
  • Aurobindo Pharma’s arm gets USFDA’s final nod for Testosterone Cypionate Injection
    23rd Oct 2023, 14:40 PM

    The product is expected to be launched in November 2023

    Read More
  • Aurobindo Pharma’s step-down arm inaugurates green-field manufacturing Unit at Vishakhapatnam
    16th Oct 2023, 14:37 PM

    This Unit will manufacture general injectables and expected to supply globally in phases

    Read More
  • Aurobindo Pharma’s unit recalling 9,890 bottles of Rasagiline Tablets in US
    9th Oct 2023, 16:00 PM

    New Jersey-based Aurobindo Pharma USA Inc is recalling the affected lot due to ‘Failed dissolution specifications’

    Read More
  • US FDA completes inspection at Aurobindo Pharma’s Telangana manufacturing facility
    30th Sep 2023, 10:42 AM

    US FDA has conducted inspection from September 22 to September 29, 2023

    Read More
  • Aurobindo Pharma’s arm enters into Licence agreement with Hilleman Laboratories Singapore
    28th Sep 2023, 12:57 PM

    Hilleman will also be paid royalties upon commercialization of the vaccine candidate

    Read More
  • USFDA completes inspection at formulation manufacturing facility of Aurobindo Pharma’s arm
    20th Sep 2023, 10:30 AM

    At the end of the inspection, a ‘Form 483’ was issued with 1 observation which is procedural in nature

    Read More
  • Aurobindo Pharma gets EIR for Telangana manufacturing facility
    7th Sep 2023, 12:00 PM

    The said facility classified as Voluntary Action Indicated

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.